research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim
New cancer treatments are more precise and less toxic, improving survival rates, but Asia faces challenges in adopting these advancements.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research KRT17: A Key Driver of Cancer Therapy Resistance and Emerging Therapeutic Target
Targeting Keratin 17 may help overcome cancer therapy resistance.
research Trichomegaly of the eyelashes following treatment with cetuximab
Cetuximab can cause excessive eyelash growth.
research Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity
A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
research Dormant tumor cells in ret transgenic mouse melanoma model and their interaction with memory T cells
Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo
TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
research Incidence and management of cutaneous toxicities associated with cetuximab
Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
research 증례 : 몸통의 다발성 판으로 나타난 Bortezomib에 의한 약물 발진 2예
Bortezomib chemotherapy can cause temporary skin rashes.
research Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings
Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.
research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
research SUN-911 Immunotherapy Use in Adrenocortical Carcinoma with Encouraging Results- a Case Report
Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
research Alopecia Areata: Hair and Nail Findings in a Patient Undergoing Talquetamab Therapy for Multiple Myeloma
Talquetamab may cause hair loss and skin issues.
research Cetuximab-induced hypertrichosis of the scalp and eyelashes
A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.
research The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
research Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata
research Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
research The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research A humanized IL-2 fusion protein enhances T regulatory cells in vivo and restrains disease in a murine model of Alopecia Areata 4760
A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.
research Docetaxel and permanent alopecia
Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
CT-707 is effective and safe for treating certain Chinese lung cancer patients.
research Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab
research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.